Energy Dome Closes 40 Million Euro Series B Financing Round
27.4.2023 08:00:00 EEST | Business Wire | Press release
Energy Dome, the company behind the CO2 Battery™, the innovative long-duration energy storage solution, today announced it has closed a 40 million euro (circa $44 million) Series B funding round.
The financing round was led by Eni Next, the corporate venture capital arm of Eni. Eni Next invests in high-growth start-ups to boost the energy transition to a zero-carbon future. Its portfolio includes start-ups with the most disruptive technologies, such as energy storage and fusion. The round was co-led by Neva SGR, the venture capital company of Intesa Sanpaolo, one of Europe’s largest banking groups. Climate tech and energy transition technologies are among the key areas of the investment strategy for Neva SGR.
Existing investors have followed Energy Dome’s Series B round, confirming their belief in the potential of the company and the team behind it, including Barclays’ Sustainable Impact Capital, CDP Venture Capital, Italian asset management company owned by CDP Equity Spa, and Invitalia, with the aim of fostering the development of all players in the innovation ecosystem via its Evolution Fund, Novum Capital Partners, a Swiss multi-family office via its investors, and 360 Capital, a Paris- and Milan-based VC with the utility A2A as one of the main limited partners. Also joining the round is Japan Energy Fund, a specialized climate tech venture fund representing entities including Biprogy, Enechange, Mitsui Sumitomo Trust Bank and Toshiba Energy Systems. Participants in the Series B include Elemental Excelerator, a U.S. nonprofit investor focused on climate tech.
This financing round brings invested-in capital in Energy Dome to some 54 million euros. Proceeds from this investment will enable Energy Dome to enter full commercial scaling mode on a global basis.
After the successful closing, Claudio Spadacini, Energy Dome’s Founder and CEO, shared his message to the market: “Imagine a system that can store renewable energy with 75% RTE (AC-AC, MV-MV) and a cost which is half the cost of lithium. A system that has no degradation over 30 years and that is made of just steel, water and CO2. Now imagine that that system is made of existing and well-known components that any power plant operator is capable of maintaining and operating, and those components are deployable at GWh scale globally with no bottlenecks on the supply chain or specific site constraints. If you like this idea, stop imagining. Because this is reality, the technology is sorted. Our CO2 Battery™ is ready for the market and, after closing the Series B round, we are ready to guarantee its performance to any customer that is real about getting rid of fossil fuels and substituting with dispatchable renewable energies.”
Energy Dome’s solution for long-duration energy storage is achieving an enthusiastic reception in the global marketplace. Energy Dome is already working with several utilities, independent power producers and corporate customers in key markets, resulting in a qualified pipeline that exceeds 9GWh in markets such as the U.S., Europe, South America, India and Australia. The Company’s short-term objective is to keep up the momentum gained so far; Energy Dome went from start of operation to full commercial-scale deployment in just three years and will have two standard 20MW-200MWh frames commercially operational by the end of 2024. The first unit is already under manufacturing, with the longest leading items being manufactured by key suppliers.
More About the Round
With participation from well-capitalized international investors, this Series B round will enable further commercialization of Energy Dome’s technology around the world and will support the expansion of Energy Dome’s team in key markets, with a specific focus on the U.S.
The use of proceeds of the round will serve to provide financial guarantees to customers as a demonstration that this team is ready to put their “skin in the game” alongside their customers in deploying the CO2 Battery™. The investment will also support Energy Dome’s business expansion in the U.S. in order to leverage at maximum from the opportunities deriving from the Inflation Reduction Act and the associated Investment Tax Credits available for utility-scale energy storage.
About Energy Dome
Energy Dome is revolutionizing energy storage and enabling grid decarbonization by making solar and wind power dispatchable 24/7. The company invented and developed the CO2 Battery™, a long-duration energy storage system that makes long-duration energy storage viable globally today. The properties of carbon dioxide allow the system to store energy efficiently and cost-effectively, with a modular and site-independent footprint. CO2 Batteries™ use readily available, off-the-shelf components from reliable, existing supply chains, providing a pathway to store massive amounts of intermittent renewable energy and accelerate the energy transition. For more information, please visit www.energydome.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005016/en/
Contact information
Brent Shelton
PRforEnergyDome@bospar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 14:30:00 EEST | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “At ISPOR 2026, Organon
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 09:30:00 EEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 09:00:00 EEST | Press release
Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership enables agentic AI to scale well beyond pilot deployments. With the Experian Ascend Platform natively connected to the ServiceNow AI Platfo
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 19:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulatory compliance on behalf of developers, removing a significant operational and legal barrier for studios looking to distribute through alternat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
